Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Monoclonal Antibody
16 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Positive Results
Lilly Presents Positive Results for Taltz® vs. Humira®in Patients with Active Psoriatic Arthritis
PR-M06-19-NI-023
Phase 3
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
PR-M12-18-NI-019
Biosimilars
Another mAb Biosimilar on the Horizon in Europe
PAO-M06-18-NI-006
Monoclonal Antibody
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody
PR-M05-18-NI-083
Monoclonal antibody
Alopexx Pharmaceuticals' F598 Monoclonal Antibody Binds to poly-N-acetylglucosamine (PNAG) on Microbial Surfaces Offering Potential Protective Immunity Against Multiple Pathogens
PR-M04-18-NI-36
Drug Development
WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development
PR-M02-18-NI-049
Clinical Trials
Tyzivumab is Ready for Trials
PAO-M02-18-NI-011
Cell Line Development
Abzena and UGA Team Up to Develop MS Therapeutic
PAO-M10-17-NI-033
Innovation
Bone Marrow Transplant Therapy Gets Monoclonal Antibody Boost
PAO-M10-17-NI-015
Monoclonal Antibodies
New Entamoeba Histolytica Monoclonal Antibodies
PR-M08-17-NI-001
Clinical Trials
Novel Pneumonia-Fighter Enters Pivotal Trial
PAO-M08-17-NI-011
Innovation
CMC and Trellis Agree to Develop mAb Therapies to Treat Viral, Bacterial Infections
PAO-M08-17-NI-010
Facility
WuXi Passes Pre-License Inspection for mAb-Based HIV Treatment Production
PAO-M08-17-NI-008
Oncology
Telix and OBI License Abzena Cancer Fighters
PAO-M07-17-NI-029
FDA
FDA Fast Track Designation Granted for Pfizer and Eli Lilly’s Innovative Pain Treatment
PAO-M06-17-NI-010
FDA Approval
Fresh RA Treatment from Sanofi/Regeneron Approved
PAO-M05-17-NI-024
